Bristol-Myers Squibb Company (BMY) Stock Forecast, Price Target & Predictions
BMY Stock Forecast
Bristol-Myers Squibb Company stock forecast is as follows: an average price target of $65.43 (represents a 33.18% upside from BMY’s last price of $49.13) and a rating consensus of 'Hold', based on 17 wall street analysts offering a 1-year stock forecast.
BMY Price Target
The average price target for Bristol-Myers Squibb Company (BMY) is $65.43 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $85.00 to $41.00. This represents a potential 33.18% upside from BMY's last price of $49.13.
BMY Analyst Ratings
According to 17 Wall Street analysts, Bristol-Myers Squibb Company's rating consensus is 'Hold'. The analyst rating breakdown for BMY stock is 0 'Strong Buy' (0.00%), 6 'Buy' (35.29%), 10 'Hold' (58.82%), 1 'Sell' (5.88%), and 0 'Strong Sell' (0.00%).
Bristol-Myers Squibb Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 29, 2024 | Chris Shibutani | Goldman Sachs | $57.00 | $50.55 | 12.77% | 16.02% |
| Jul 29, 2024 | Carter Gould | Barclays | $41.00 | $50.45 | -18.73% | -16.55% |
| Jul 12, 2024 | Trung Huynh | UBS | $43.00 | $40.68 | 5.70% | -12.48% |
| May 16, 2024 | Steve Scala | Cowen & Co. | $67.00 | $44.11 | 51.89% | 36.37% |
| Jan 30, 2024 | James Shin | Deutsche Bank | $55.00 | $49.87 | 10.29% | 11.95% |
| Nov 27, 2023 | Evan Seigerman | BMO Capital | $60.00 | $49.76 | 20.58% | 22.12% |
| Oct 12, 2023 | David Risinger | Leerink Partners | $66.00 | $56.24 | 17.34% | 34.34% |
| Sep 06, 2023 | Louise Chen | Cantor Fitzgerald | $75.00 | $59.67 | 25.69% | 52.66% |
| May 18, 2022 | Mohit Bansal | Wells Fargo | $70.00 | $78.22 | -10.51% | 42.48% |
| May 02, 2022 | - | BMO Capital | $92.00 | $75.66 | 21.60% | 87.26% |
The latest Bristol-Myers Squibb Company stock forecast, released on Jul 29, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $57.00, which represents a 12.77% increase from the stock price at the time of the forecast ($50.55), and a 16.02% increase from BMY last price ($49.13).
Bristol-Myers Squibb Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 7 |
| Avg Price Target | - | $47.00 | $55.57 |
| Last Closing Price | $49.13 | $49.13 | $49.13 |
| Upside/Downside | -100.00% | -4.34% | 13.11% |
In the current month, the average price target of Bristol-Myers Squibb Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bristol-Myers Squibb Company's last price of $49.13. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Jefferies | Hold | Hold | Hold |
| Aug 22, 2024 | Deutsche Bank | Equal-Weight | Equal-Weight | Hold |
| Aug 22, 2024 | Barclays | Underweight | Underweight | Hold |
| Aug 12, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Jul 29, 2024 | Deutsche Bank | Hold | Hold | Hold |
| Jul 29, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 29, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jul 29, 2024 | Barclays | Equal-Weight | Underweight | Downgrade |
| Jul 22, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Jul 22, 2024 | Cantor Fitzgerald | Market Perform | Market Perform | Hold |
Bristol-Myers Squibb Company's last stock rating was published by Jefferies on Aug 28, 2024. The company gave BMY a "Hold" rating, the same as its previous rate.
Bristol-Myers Squibb Company Financial Forecast
Bristol-Myers Squibb Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | - | $11.65B | $11.98B | $11.62B | $11.70B | $11.07B | $11.07B | $10.54B | $10.13B | $10.78B | $7.95B | $6.01B |
| Avg Forecast | $11.35B | $11.27B | $11.37B | $10.98B | $11.89B | $11.59B | $12.09B | $11.88B | $11.47B | $11.29B | $11.54B | $11.48B | $11.19B | $10.96B | $11.77B | $11.50B | $11.19B | $11.14B | $11.42B | $11.36B | $12.04B | $11.61B | $11.27B | $11.13B | $10.73B | $10.32B | $9.99B | $10.03B | $7.12B | $5.90B |
| High Forecast | $11.79B | $11.70B | $11.81B | $11.41B | $12.35B | $12.05B | $12.56B | $12.34B | $11.92B | $11.49B | $11.99B | $11.93B | $11.53B | $11.16B | $12.22B | $11.94B | $11.62B | $11.57B | $11.42B | $11.64B | $12.34B | $11.90B | $11.55B | $11.40B | $10.99B | $10.58B | $10.24B | $10.27B | $7.30B | $6.04B |
| Low Forecast | $11.07B | $10.98B | $11.08B | $10.71B | $11.59B | $11.30B | $11.78B | $11.58B | $11.19B | $11.09B | $11.25B | $11.19B | $10.78B | $10.82B | $11.47B | $11.21B | $10.90B | $10.86B | $11.42B | $11.10B | $11.77B | $11.35B | $11.01B | $10.87B | $10.48B | $10.08B | $9.76B | $9.80B | $6.96B | $5.76B |
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.95% | 0.99% | 1.02% | 1.01% | - | 1.03% | 1.00% | 1.00% | 1.04% | 0.99% | 1.03% | 1.02% | 1.01% | 1.08% | 1.12% | 1.02% |
Bristol-Myers Squibb Company's average Quarter revenue forecast for Dec 23 based on 9 analysts is $11.19B, with a low forecast of $10.78B, and a high forecast of $11.53B. BMY's average Quarter revenue forecast represents a 2.06% increase compared to the company's last Quarter revenue of $10.97B (Sep 23).
Bristol-Myers Squibb Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.21B | $4.16B | $5.10B | $4.71B | $5.30B | - | $5.08B | $4.76B | $5.21B | $4.59B | $5.54B | $-7.41B | $5.25B | $4.54B | $2.53B | $1.39B | $1.72B |
| Avg Forecast | $4.30B | $4.27B | $4.31B | $4.16B | $4.50B | $4.39B | $4.58B | $4.50B | $4.35B | $4.28B | $4.37B | $5.03B | $4.24B | $4.15B | $4.46B | $4.57B | $4.24B | $5.49B | $4.32B | $4.15B | $4.38B | $4.99B | $4.47B | $5.79B | $-7.14B | $4.80B | $4.08B | $2.14B | $852.95M | $1.56B |
| High Forecast | $4.47B | $4.43B | $4.47B | $4.32B | $4.68B | $4.56B | $4.76B | $4.67B | $4.51B | $4.35B | $4.54B | $6.03B | $4.37B | $4.23B | $4.63B | $5.48B | $4.40B | $6.59B | $4.32B | $4.99B | $5.26B | $5.99B | $5.36B | $6.94B | $-5.71B | $5.76B | $4.89B | $2.56B | $1.02B | $1.87B |
| Low Forecast | $4.19B | $4.16B | $4.20B | $4.06B | $4.39B | $4.28B | $4.46B | $4.39B | $4.24B | $4.20B | $4.26B | $4.02B | $4.08B | $4.10B | $4.34B | $3.66B | $4.13B | $4.39B | $4.32B | $3.32B | $3.51B | $3.99B | $3.57B | $4.63B | $-8.57B | $3.84B | $3.26B | $1.71B | $682.36M | $1.24B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 0.93% | 1.12% | 1.11% | 0.97% | - | 1.22% | 1.09% | 1.04% | 1.03% | 0.96% | 1.04% | 1.09% | 1.11% | 1.18% | 1.63% | 1.10% |
9 analysts predict BMY's average Quarter EBITDA for Dec 23 to be $4.24B, with a high of $4.37B and a low of $4.08B. This is 0.57% upper than Bristol-Myers Squibb Company's previous annual EBITDA (Sep 23) of $4.21B.
Bristol-Myers Squibb Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | - | $1.28B | $2.37B | $1.55B | $1.05B | $2.02B | $-10.03B | $1.87B | $-85.00M | $-775.00M | $-1.06B | $1.35B |
| Avg Forecast | $3.75B | $3.80B | $3.75B | $3.24B | $3.65B | $3.72B | $4.06B | $3.84B | $3.05B | $3.23B | $3.29B | $1.51B | $3.15B | $3.58B | $3.98B | $1.37B | $3.50B | $1.63B | $3.58B | $1.24B | $2.35B | $1.48B | $1.03B | $2.11B | $-9.67B | $1.71B | $-76.39M | $-655.37M | $-648.00M | $1.23B |
| High Forecast | $3.94B | $4.00B | $3.94B | $3.40B | $3.84B | $3.91B | $4.27B | $4.03B | $3.20B | $3.41B | $3.45B | $1.81B | $3.55B | $3.78B | $4.18B | $1.64B | $3.68B | $1.96B | $3.58B | $1.49B | $2.82B | $1.78B | $1.23B | $2.53B | $-7.74B | $2.05B | $-61.11M | $-524.30M | $-518.40M | $1.47B |
| Low Forecast | $3.62B | $3.68B | $3.63B | $3.13B | $3.53B | $3.60B | $3.93B | $3.71B | $2.95B | $3.09B | $3.18B | $1.20B | $2.86B | $3.40B | $3.85B | $1.10B | $3.39B | $1.30B | $3.58B | $995.64M | $1.88B | $1.19B | $821.55M | $1.69B | $-11.61B | $1.37B | $-91.66M | $-786.44M | $-777.60M | $981.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.54% | 0.52% | 1.65% | 0.58% | 0.99% | - | 1.03% | 1.01% | 1.04% | 1.03% | 0.96% | 1.04% | 1.09% | 1.11% | 1.18% | 1.63% | 1.10% |
Bristol-Myers Squibb Company's average Quarter net income forecast for Dec 23 is $3.15B, with a range of $2.86B to $3.55B. BMY's average Quarter net income forecast represents a 63.51% increase compared to the company's last Quarter net income of $1.93B (Sep 23).
Bristol-Myers Squibb Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | - | $1.83B | $2.35B | $1.79B | $1.88B | $1.67B | $2.72B | $1.71B | $1.63B | $1.61B | $1.73B | $1.05B |
| Avg Forecast | $1.99B | $1.97B | $1.99B | $1.92B | $2.08B | $2.03B | $2.11B | $2.08B | $2.01B | $1.97B | $2.02B | $2.16B | $1.96B | $1.92B | $2.06B | $1.96B | $1.96B | $1.88B | $2.00B | $1.78B | $2.31B | $1.71B | $1.83B | $1.74B | $2.62B | $1.56B | $1.46B | $1.36B | $1.06B | $956.40M |
| High Forecast | $2.06B | $2.05B | $2.07B | $2.00B | $2.16B | $2.11B | $2.20B | $2.16B | $2.08B | $2.01B | $2.10B | $2.59B | $2.02B | $1.95B | $2.14B | $2.35B | $2.03B | $2.26B | $2.00B | $2.14B | $2.78B | $2.06B | $2.20B | $2.09B | $3.15B | $1.87B | $1.76B | $1.63B | $1.28B | $1.15B |
| Low Forecast | $1.94B | $1.92B | $1.94B | $1.87B | $2.03B | $1.98B | $2.06B | $2.02B | $1.96B | $1.94B | $1.97B | $1.73B | $1.88B | $1.89B | $2.01B | $1.57B | $1.91B | $1.51B | $2.00B | $1.43B | $1.85B | $1.37B | $1.47B | $1.39B | $2.10B | $1.25B | $1.17B | $1.09B | $851.24M | $765.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 0.94% | 0.90% | 1.16% | 1.02% | - | 1.03% | 1.02% | 1.04% | 1.03% | 0.96% | 1.04% | 1.09% | 1.11% | 1.18% | 1.63% | 1.10% |
Bristol-Myers Squibb Company's average Quarter SG&A projection for Dec 23 is $1.96B, based on 9 Wall Street analysts, with a range of $1.88B to $2.02B. The forecast indicates a -2.30% fall compared to BMY last annual SG&A of $2.00B (Sep 23).
Bristol-Myers Squibb Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.94 | $0.99 | $1.08 | $0.96 | $0.75 | - | $0.60 | $1.10 | $0.70 | $0.47 | $0.90 | $-4.45 | $0.83 | $-0.04 | $-0.34 | $-0.55 | $0.83 |
| Avg Forecast | $1.85 | $1.87 | $1.85 | $1.60 | $1.80 | $1.83 | $2.00 | $1.89 | $1.50 | $1.59 | $1.62 | $-4.41 | $1.55 | $1.76 | $1.96 | $1.97 | $1.73 | $1.83 | $1.77 | $1.91 | $1.80 | $1.92 | $1.89 | $1.81 | $1.42 | $1.49 | $1.48 | $1.49 | $0.88 | $1.07 |
| High Forecast | $1.94 | $1.97 | $1.94 | $1.68 | $1.89 | $1.93 | $2.10 | $1.99 | $1.58 | $1.68 | $1.70 | $-4.27 | $1.75 | $1.86 | $2.06 | $2.07 | $1.81 | $1.92 | $1.77 | $1.98 | $1.85 | $1.98 | $1.95 | $1.86 | $1.46 | $1.54 | $1.53 | $1.53 | $0.91 | $1.11 |
| Low Forecast | $1.79 | $1.81 | $1.79 | $1.54 | $1.74 | $1.77 | $1.94 | $1.83 | $1.45 | $1.52 | $1.57 | $-4.64 | $1.41 | $1.67 | $1.90 | $1.91 | $1.67 | $1.77 | $1.77 | $1.86 | $1.74 | $1.86 | $1.83 | $1.75 | $1.37 | $1.45 | $1.44 | $1.44 | $0.86 | $1.04 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.53% | 0.50% | 0.55% | 0.56% | 0.41% | - | 0.31% | 0.61% | 0.36% | 0.25% | 0.50% | -3.14% | 0.56% | -0.03% | -0.23% | -0.62% | 0.77% |
According to 9 Wall Street analysts, Bristol-Myers Squibb Company's projected average Quarter EPS for Dec 23 is $1.55, with a low estimate of $1.41 and a high estimate of $1.75. This represents a 65.29% increase compared to BMY previous annual EPS of $0.94 (Sep 23).
Bristol-Myers Squibb Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $29.27 | $46.29 | 58.15% | Hold |
| BIIB | Biogen | $195.63 | $291.45 | 48.98% | Buy |
| BMY | Bristol-Myers Squibb Company | $49.13 | $65.43 | 33.18% | Hold |
| MRK | Merck | $115.86 | $127.74 | 10.25% | Buy |
| JNJ | Johnson & Johnson | $165.52 | $176.29 | 6.51% | Buy |
| GILD | Gilead Sciences | $82.81 | $80.00 | -3.39% | Buy |
| AMGN | Amgen | $332.45 | $286.95 | -13.69% | Buy |
| ABBV | AbbVie | $194.21 | $167.54 | -13.73% | Buy |
| LLY | Eli Lilly and Company | $923.71 | $753.65 | -18.41% | Buy |
BMY Forecast FAQ
Is Bristol-Myers Squibb Company a good buy?
No, according to 17 Wall Street analysts, Bristol-Myers Squibb Company (BMY) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 35.29% of BMY's total ratings.
What is BMY's price target?
Bristol-Myers Squibb Company (BMY) average price target is $65.43 with a range of $41 to $85, implying a 33.18% from its last price of $49.13. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bristol-Myers Squibb Company stock go up soon?
According to Wall Street analysts' prediction for BMY stock, the company can go up by 33.18% (from the last price of $49.13 to the average price target of $65.43), up by 73.01% based on the highest stock price target, and down by -16.55% based on the lowest stock price target.
Can Bristol-Myers Squibb Company stock reach $70?
BMY's highest twelve months analyst stock price target of $85 supports the claim that Bristol-Myers Squibb Company can reach $70 in the near future.
What are Bristol-Myers Squibb Company's analysts' financial forecasts?
Bristol-Myers Squibb Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $47.45B (high $49.29B, low $46.25B), average EBITDA is $17.97B (high $18.67B, low $17.52B), average net income is $15.27B (high $16.04B, low $14.77B), average SG&A $8.3B (high $8.62B, low $8.09B), and average EPS is $7.53 (high $7.91, low $7.28). BMY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $44.98B (high $46.72B, low $43.84B), average EBITDA is $17.03B (high $17.7B, low $16.6B), average net income is $14.54B (high $15.27B, low $14.06B), average SG&A $7.86B (high $8.17B, low $7.67B), and average EPS is $7.17 (high $7.53, low $6.93).
Did the BMY's actual financial results beat the analysts' financial forecasts?
Based on Bristol-Myers Squibb Company's last annual report (Dec 2023), the company's revenue was $45.01B, which missed the average analysts forecast of $45.41B by -0.89%. Apple's EBITDA was $17.24B, missing the average prediction of $17.41B by -0.99%. The company's net income was $8.02B, missing the average estimation of $12.08B by -33.57%. Apple's SG&A was $7.77B, missing the average forecast of $7.89B by -1.51%. Lastly, the company's EPS was $3.88, missing the average prediction of $7.25 by -46.49%. In terms of the last quarterly report (Sep 2023), Bristol-Myers Squibb Company's revenue was $10.97B, beating the average analysts' forecast of $10.96B by 0.10%. The company's EBITDA was $4.22B, beating the average prediction of $4.15B by 1.59%. Bristol-Myers Squibb Company's net income was $1.93B, missing the average estimation of $3.58B by -46.14%. The company's SG&A was $2B, beating the average forecast of $1.92B by 4.56%. Lastly, the company's EPS was $0.94, missing the average prediction of $1.76 by -46.72%